Background: Kidney transplantation (KT) is the optimal treatment for end stage renal disease. However, the relative shortage of organs for transplantation (from human leukocyte antigen-or ABO incompatible [ABOi] living donors) has led to ABOi KT as an accepted method to expand the pool of living kidney donors. To date, reports of the outcomes of ABOi KT are limited; therefore this study aims to evaluate the outcomes of ABOi KT in recipients.
추적관찰 기간 동안 모든 환자의 IgG 및 IgM 항 ABO 혈액형 항체역가의 순차적 변화는 다음과 같다 (Fig. 2) . 
